Skip to main content

Table 1 Baseline characteristics of healthy volunteers whose miRNA levels were quantified

From: Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban

 

Total

Group classified by AXA3h

Group classified by AUC0-t

Overall

Case

Control

p value

Overall

Case

Control

p value

10 mg

 n

26

20

10

10

1.000

20

10

10

1.000

 Male

15 (57.69%)

11 (55.00%)

4 (40.00%)

7 (70.00%)

0.370

12 (60.00%)

8 (80.00%)

4 (40.00%)

0.170

 Fed

13 (50.00%)

10 (50.00%)

5 (50.00%)

5 (50.00%)

1.000

10 (50.00%)

5 (50.00%)

5 (50.00%)

1.000

 Age

32 (13)

34 (16)

37.5 (16)

31.5 (14)

0.579

35.5 (15)

33 (14)

36 (14)

0.796

 BMI

23.35 (1.8)

23.35 (1.70)

23.40 (2.50)

22.60 (1.60)

0.853

23.40 (2.00)

23.10 (2.10)

23.40 (1.80)

0.912

 AXA3h

134.04 (70.98)

134.58 (123.28)

195.93 (74.51)

86.28 (32.26)

0.000*

117.08 (78.49)

92.95 (35.58)

167.41 (64.05)

0.000*

 C3

163.1745 (108.41)

160.95 (104.41)

197.43 (85.37)

103.34 (45.57)

0.000*

146.36 (99.96)

103.34 (42.82)

194.46 (62.13)

0.000*

 Cmax

191.9635 (69.81)

188.00 (96.67)

225.14 (78.56)

137.44 (78.92)

0.003*

187.16 (82.93)

137.44 (67.60)

215.98 (57.62)

0.001*

 AUC0-t

1302.5875 (751.46)

1231.48 (780.15)

1633.65 (622.65)

910.76 (415.46)

0.000*

1350.74 (866.89)

840.75 (354.44)

1702.33 (316.65)

0.000*

15 mg

 n

39

28

14

14

1.000

28

14

14

1.000

 Male

33 (84.62%)

23 (82.14%)

10 (71.43%)

13 (92.86%)

0.326

23 (82.14%)

13 (92.86%)

10 (71.43%)

0.326

 Fed

21 (53.85%)

14 (50.00%)

7 (50.00%)

7 (50.00%)

1.000

14 (50.00%)

7 (50.00%)

7 (50.00%)

1.000

 Age

29 (10)

27 (11)

24 (8)

30 (11)

0.114

25 (9)

27 (10)

24.5 (9)

0.401

 BMI

22.2 (3.2)

22.10 (2.70)

21.70 (2.30)

23.20 (2.90)

0.401

23.10 (3.30)

23.30 (3.50)

22.55 (3.40)

0.804

 AXA3h

171.22 (175.59)

164.39 (219.13)

273.28 (79.31)

54.78 (113.13)

0.000*

169.96 (155.77)

93.07 (109.99)

221.93 (75.05)

0.000*

 C3

208 (183)

210.00 (224.25)

329.50 (75.75)

107.00 (75.75)

0.000*

203.00 (169.50)

129.00 (99.00)

277.00 (100.75)

0.000*

 Cmax

283 (164)

284.00 (172.75)

358.50 (53.75)

196.00 (78.75)

0.000*

283.00 (136.25)

201.50 (86.25)

326.00 (86.50)

0.000*

 AUC0-t

1782.71 (1212.23)

1816.22 (1123.77)

2118.18 (542.33)

1090.19 (491.24)

0.000*

1728.31 (1402.69)

1074.30 (468.58)

2440.31 (653.37)

0.000*

  1. Values are median (IQR), n (%)
  2. IQR interquartile range; AXA3h anti-Xa activity measured 3 h after rivaroxaban administration, AUC0-t area under the plasma concentration time-curve from time 0 to time of last determinable concentration, BMI body mass index, C3 plasma concentration 3 h after administration, Cmax maximum plasma concentration
  3. *p < 0.05